Liraglutide  	Liraglutide  	 NNP	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
type  	type  	 NN	O
2  	2  	 CD	O
diabetes  	diabetes  	 NN	O
This  	This  	 DT	O
paper  	paper  	 NN	O
presents  	presents  	 VBZ	O
a  	a  	 DT	O
summary  	summary  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
evidence  	evidence  	 NN	B-NP
review  	review  	 NN	I-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
ERG 	ERG 	 NNP	O
)  	)  	 -RRB-	O
report  	report  	 NN	O
into  	into  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
effectiveness  	effectiveness  	 NN	I-NP
and  	and  	 CC	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
liraglutide  	liraglutide  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
type  	type  	 NN	O
2  	2  	 CD	O
diabetes  	diabetes  	 NN	B-NP
mellitus 	mellitus 	 NN	I-NP
,  	,  	 ,	O
based  	based  	 VBN	O
upon  	upon  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
submission  	submission  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
National  	National  	 NNP	O
Institute  	Institute  	 NNP	O
for  	for  	 IN	O
Health  	Health  	 NNP	O
and  	and  	 CC	O
Clinical  	Clinical  	 NNP	B-NP
Excellence  	Excellence  	 NNP	I-NP
( 	( 	 -LRB-	O
NICE 	NICE 	 NNP	O
)  	)  	 -RRB-	O
as  	as  	 IN	O
part  	part  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
single  	single  	 JJ	O
technology  	technology  	 NN	B-NP
appraisal  	appraisal  	 NN	I-NP
process 	process 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
manufacturer  	manufacturer  	 NN	B-NP
proposed  	proposed  	 VBD	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
liraglutide  	liraglutide  	 NN	B-NP
as  	as  	 IN	O
a  	a  	 DT	O
second  	second  	 JJ	O
or  	or  	 CC	O
third  	third  	 JJ	O
drug  	drug  	 NN	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
type  	type  	 NN	O
2  	2  	 CD	O
diabetes  	diabetes  	 NN	O
whose  	whose  	 WP$	O
glycaemic  	glycaemic  	 JJ	B-NP
control  	control  	 NN	I-NP
was  	was  	 VBD	O
unsatisfactory  	unsatisfactory  	 VBN	O
with  	with  	 IN	O
metformin 	metformin 	 NN	B-NP
,  	,  	 ,	O
with  	with  	 IN	O
or  	or  	 CC	O
without  	without  	 IN	O
a  	a  	 DT	O
second  	second  	 JJ	O
oral  	oral  	 JJ	B-NP
glucose-lowering  	glucose-lowering  	 JJ	I-NP
drug 	drug 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
submission  	submission  	 NN	O
included  	included  	 VBD	O
six  	six  	 CD	O
manufacturer-sponsored  	manufacturer-sponsored  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
that  	that  	 IN	O
compared  	compared  	 VBN	O
the  	the  	 DT	O
efficacy  	efficacy  	 NN	O
of  	of  	 IN	O
liraglutide  	liraglutide  	 NN	B-NP
against  	against  	 IN	O
other  	other  	 JJ	O
glucose-lowering  	glucose-lowering  	 JJ	O
agents 	agents 	 NNS	O
.  	.  	 .	O
Not  	Not  	 RB	O
all  	all  	 RB	O
of  	of  	 IN	O
the  	the  	 DT	O
trials  	trials  	 NNS	O
were  	were  	 VBD	O
relevant  	relevant  	 JJ	O
to  	to  	 TO	O
the  	the  	 DT	O
decision  	decision  	 NN	B-NP
problem 	problem 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
most  	most  	 RBS	O
relevant  	relevant  	 JJ	O
were  	were  	 VBD	O
Liraglutide  	Liraglutide  	 NNP	B-NP
Effects  	Effects  	 NNPS	I-NP
and  	and  	 CC	I-NP
Actions  	Actions  	 NNP	I-NP
in  	in  	 IN	I-NP
Diabetes  	Diabetes  	 NNP	I-NP
5  	5  	 CD	I-NP
( 	( 	 -LRB-	O
LEAD-5 	LEAD-5 	 NNP	B-NP
)  	)  	 -RRB-	O
( 	( 	 -LRB-	O
liraglutide  	liraglutide  	 VB	O
used  	used  	 VBN	O
as  	as  	 IN	O
part  	part  	 NN	O
of  	of  	 IN	O
triple  	triple  	 JJ	O
therapy  	therapy  	 NN	O
and  	and  	 CC	O
compared  	compared  	 VBN	O
against  	against  	 IN	O
insulin  	insulin  	 NN	B-NP
glargine 	glargine 	 NN	I-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
LEAD-6  	LEAD-6  	 NNP	B-NP
[ 	[ 	 -LRB-	O
liraglutide  	liraglutide  	 NN	B-NP
in  	in  	 IN	O
triple  	triple  	 JJ	O
therapy  	therapy  	 NN	O
compared  	compared  	 VBN	O
against  	against  	 IN	O
another  	another  	 DT	O
glucagon-like  	glucagon-like  	 JJ	B-NP
peptide-1  	peptide-1  	 CD	I-NP
agonist 	agonist 	 NN	I-NP
,  	,  	 ,	O
exenatide 	exenatide 	 CD	B-NP
] 	] 	 -RRB-	O
.  	.  	 .	O
Five  	Five  	 CD	O
of  	of  	 IN	O
the  	the  	 DT	O
six  	six  	 CD	O
trials  	trials  	 NNS	O
were  	were  	 VBD	O
published  	published  	 VBN	O
in  	in  	 IN	O
full  	full  	 JJ	O
and  	and  	 CC	O
one  	one  	 PRP	O
was  	was  	 VBD	O
then  	then  	 RB	O
unpublished 	unpublished 	 JJ	O
.  	.  	 .	O
Two  	Two  	 CD	O
doses  	doses  	 NNS	O
of  	of  	 IN	O
liraglutide 	liraglutide 	 NN	B-NP
,  	,  	 ,	O
1.2  	1.2  	 CD	O
and  	and  	 CC	O
1.8  	1.8  	 CD	O
mg 	mg 	 NN	B-NP
,  	,  	 ,	O
were  	were  	 VBD	O
used  	used  	 VBN	O
in  	in  	 IN	O
some  	some  	 DT	O
trials 	trials 	 NNS	O
,  	,  	 ,	O
but  	but  	 CC	O
in  	in  	 IN	O
the  	the  	 DT	O
two  	two  	 CD	O
comparisons  	comparisons  	 NNS	O
in  	in  	 IN	O
triple  	triple  	 JJ	O
therapy 	therapy 	 NN	O
,  	,  	 ,	O
against  	against  	 IN	O
glargine  	glargine  	 NN	B-NP
and  	and  	 CC	O
exenatide 	exenatide 	 NN	B-NP
,  	,  	 ,	O
only  	only  	 RB	O
the  	the  	 DT	O
1.8-mg  	1.8-mg  	 JJ	O
dose  	dose  	 NN	O
was  	was  	 VBD	O
used 	used 	 VBN	O
.  	.  	 .	O
Liraglutide  	Liraglutide  	 NNP	B-NP
in  	in  	 IN	O
both  	both  	 DT	O
doses  	doses  	 NNS	O
was  	was  	 VBD	O
found  	found  	 VBN	O
to  	to  	 TO	O
be  	be  	 VB	O
clinically  	clinically  	 RB	O
effective  	effective  	 JJ	O
in  	in  	 IN	O
lowering  	lowering  	 VBG	B-NP
blood  	blood  	 NN	I-NP
glucose  	glucose  	 NN	I-NP
concentration  	concentration  	 NN	I-NP
[ 	[ 	 -LRB-	O
glycated  	glycated  	 FW	O
haemoglobin  	haemoglobin  	 FW	B-NP
( 	( 	 -LRB-	O
HbA1c 	HbA1c 	 NNP	O
) 	) 	 -RRB-	O
] 	] 	 -RRB-	O
,  	,  	 ,	O
reducing  	reducing  	 VBG	B-NP
weight  	weight  	 NN	I-NP
( 	( 	 -LRB-	O
unlike  	unlike  	 IN	O
other  	other  	 JJ	O
glucose-lowering  	glucose-lowering  	 JJ	O
agents 	agents 	 NNS	O
,  	,  	 ,	O
such  	such  	 JJ	O
as  	as  	 IN	O
sulphonylureas 	sulphonylureas 	 NN	B-NP
,  	,  	 ,	O
glitazones  	glitazones  	 NN	B-NP
and  	and  	 CC	O
insulins 	insulins 	 NNS	O
,  	,  	 ,	O
which  	which  	 WDT	O
cause  	cause  	 VBP	O
weight  	weight  	 NN	B-NP
gain 	gain 	 NN	I-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
also  	also  	 RB	O
reducing  	reducing  	 VBG	O
systolic  	systolic  	 JJ	B-NP
blood  	blood  	 NN	I-NP
pressure  	pressure  	 NN	I-NP
( 	( 	 -LRB-	O
SBP 	SBP 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Hypoglycaemia  	Hypoglycaemia  	 NNP	B-NP
was  	was  	 VBD	O
uncommon 	uncommon 	 JJ	O
.  	.  	 .	O
The  	The  	 DT	O
ERG  	ERG  	 NNP	O
carried  	carried  	 VBD	O
out  	out  	 RP	O
meta-analyses  	meta-analyses  	 JJ	B-NP
comparing  	comparing  	 VBG	O
the  	the  	 DT	O
1.2-  	1.2-  	 NNP	O
and  	and  	 CC	O
1.8-mg  	1.8-mg  	 CD	O
doses  	doses  	 NNS	O
of  	of  	 IN	O
liraglutide 	liraglutide 	 NN	B-NP
,  	,  	 ,	O
which  	which  	 WDT	O
suggested  	suggested  	 VBD	O
that  	that  	 IN	O
there  	there  	 EX	O
was  	was  	 VBD	O
no  	no  	 DT	O
difference  	difference  	 NN	O
in  	in  	 IN	O
control  	control  	 NN	O
of  	of  	 IN	O
diabetes 	diabetes 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
only  	only  	 RB	O
a  	a  	 DT	O
slight  	slight  	 JJ	O
difference  	difference  	 NN	O
in  	in  	 IN	O
weight  	weight  	 NN	B-NP
loss 	loss 	 NN	I-NP
,  	,  	 ,	O
insufficient  	insufficient  	 JJ	O
to  	to  	 TO	O
justify  	justify  	 VB	O
the  	the  	 DT	O
extra  	extra  	 JJ	O
cost 	cost 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
analysis  	analysis  	 NN	I-NP
was  	was  	 VBD	O
carried  	carried  	 VBN	O
out  	out  	 RP	O
using  	using  	 VBG	O
the  	the  	 DT	O
Center  	Center  	 NNP	O
for  	for  	 IN	O
Outcomes  	Outcomes  	 NNP	O
Research  	Research  	 NNP	B-NP
model 	model 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
health  	health  	 NN	B-NP
benefit  	benefit  	 NN	I-NP
was  	was  	 VBD	O
reported  	reported  	 VBN	O
as  	as  	 IN	O
quality-adjusted  	quality-adjusted  	 JJ	B-NP
life-years  	life-years  	 NN	I-NP
( 	( 	 -LRB-	O
QALYs 	QALYs 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
manufacturer  	manufacturer  	 NN	B-NP
estimated  	estimated  	 VBD	O
the  	the  	 DT	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
to  	to  	 TO	O
be  	be  	 VB	O
£  	£  	 CD	O
15,130  	15,130  	 CD	O
per  	per  	 IN	O
QALY  	QALY  	 NNP	B-NP
for  	for  	 IN	I-NP
liraglutide  	liraglutide  	 CD	I-NP
1.8  	1.8  	 CD	O
mg  	mg  	 NNS	B-NP
compared  	compared  	 VBN	O
with  	with  	 IN	O
glargine 	glargine 	 NN	B-NP
,  	,  	 ,	O
£  	£  	 FW	O
10,054  	10,054  	 FW	O
per  	per  	 FW	O
QALY  	QALY  	 NNP	B-NP
for  	for  	 IN	I-NP
liraglutide  	liraglutide  	 CD	I-NP
1.8  	1.8  	 CD	O
mg  	mg  	 NNS	B-NP
compared  	compared  	 VBN	O
with  	with  	 IN	O
exenatide 	exenatide 	 NN	B-NP
,  	,  	 ,	O
£  	£  	 FW	O
10,465  	10,465  	 FW	O
per  	per  	 FW	O
QALY  	QALY  	 NNP	B-NP
for  	for  	 IN	I-NP
liraglutide  	liraglutide  	 CD	I-NP
1.8  	1.8  	 CD	O
mg  	mg  	 NNS	B-NP
compared  	compared  	 VBN	O
with  	with  	 IN	O
sitagliptin 	sitagliptin 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
£  	£  	 CD	O
9851  	9851  	 CD	O
per  	per  	 IN	O
QALY  	QALY  	 NNP	B-NP
for  	for  	 IN	I-NP
liraglutide  	liraglutide  	 CD	I-NP
1.2  	1.2  	 CD	O
mg  	mg  	 NNS	B-NP
compared  	compared  	 VBN	O
with  	with  	 IN	O
sitagliptin 	sitagliptin 	 NN	B-NP
.  	.  	 .	O
The  	The  	 DT	O
ERG  	ERG  	 NNP	O
conducted  	conducted  	 VBD	O
additional  	additional  	 JJ	O
sensitivity  	sensitivity  	 NN	B-NP
analyses  	analyses  	 NNS	I-NP
and  	and  	 CC	O
concluded  	concluded  	 VBD	O
that  	that  	 IN	O
the  	the  	 DT	O
factors  	factors  	 NNS	O
that  	that  	 WDT	O
carried  	carried  	 VBD	O
most  	most  	 JJS	O
weight  	weight  	 NN	O
were 	were 	 VBD	O
:  	:  	 :	O
in  	in  	 IN	O
the  	the  	 DT	O
comparison  	comparison  	 NN	O
with  	with  	 IN	O
glargine 	glargine 	 NN	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
direct  	direct  	 JJ	O
utility  	utility  	 NN	B-NP
effects  	effects  	 NNS	I-NP
of  	of  	 IN	O
body  	body  	 NN	B-NP
mass  	mass  	 NN	I-NP
index  	index  	 NN	I-NP
( 	( 	 -LRB-	O
BMI 	BMI 	 NNP	B-NP
)  	)  	 -RRB-	O
changes  	changes  	 NNS	O
and  	and  	 CC	O
SBP 	SBP 	 NNP	B-NP
,  	,  	 ,	O
with  	with  	 IN	O
some  	some  	 DT	O
additional  	additional  	 JJ	O
contribution  	contribution  	 NN	B-NP
from  	from  	 IN	O
HbA1c 	HbA1c 	 NNP	O
,  	,  	 ,	O
in  	in  	 IN	O
the  	the  	 DT	O
comparison  	comparison  	 NN	O
with  	with  	 IN	O
exenatide 	exenatide 	 NN	B-NP
,  	,  	 ,	O
HbA1c 	HbA1c 	 NNP	O
,  	,  	 ,	O
with  	with  	 IN	O
some  	some  	 DT	O
additional  	additional  	 JJ	O
effects  	effects  	 NNS	O
from  	from  	 IN	O
cholesterol  	cholesterol  	 NN	B-NP
and  	and  	 CC	O
triglycerides  	triglycerides  	 NN	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
comparison  	comparison  	 NN	O
with  	with  	 IN	O
sitagliptin 	sitagliptin 	 NN	B-NP
,  	,  	 ,	O
HbA1c  	HbA1c  	 NNP	O
and  	and  	 CC	O
direct  	direct  	 JJ	O
utility  	utility  	 NN	B-NP
effects  	effects  	 NNS	I-NP
of  	of  	 IN	I-NP
BMI  	BMI  	 NNP	I-NP
changes 	changes 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
European  	European  	 NNP	O
Medicines  	Medicines  	 NNP	O
Agency  	Agency  	 NNP	B-NP
has  	has  	 VBZ	O
approved  	approved  	 VBN	O
liraglutide  	liraglutide  	 VBN	O
in  	in  	 IN	O
dual  	dual  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
with  	with  	 IN	O
other  	other  	 JJ	O
oral  	oral  	 JJ	B-NP
glucose-lowering  	glucose-lowering  	 JJ	I-NP
agents 	agents 	 NNS	I-NP
.  	.  	 .	O
NICE  	NICE  	 JJ	O
guidance  	guidance  	 NN	O
recommends  	recommends  	 VBZ	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
liraglutide  	liraglutide  	 CD	B-NP
1.2  	1.2  	 CD	O
mg  	mg  	 NN	B-NP
in  	in  	 IN	O
triple  	triple  	 JJ	O
therapy  	therapy  	 NN	O
when  	when  	 WRB	O
glycaemic  	glycaemic  	 JJ	B-NP
control  	control  	 NN	I-NP
remains  	remains  	 VBZ	O
or  	or  	 CC	O
becomes  	becomes  	 VBZ	O
inadequate  	inadequate  	 JJ	O
with  	with  	 IN	O
a  	a  	 DT	O
combination  	combination  	 NN	O
of  	of  	 IN	O
two  	two  	 CD	O
oral  	oral  	 JJ	B-NP
glucose-lowering  	glucose-lowering  	 JJ	I-NP
drugs 	drugs 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
liraglutide  	liraglutide  	 CD	B-NP
1.2  	1.2  	 CD	O
mg  	mg  	 NN	B-NP
in  	in  	 IN	O
a  	a  	 DT	O
dual  	dual  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
is  	is  	 VBZ	O
indicated  	indicated  	 VBN	O
only  	only  	 RB	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
are  	are  	 VBP	O
intolerant  	intolerant  	 VBN	O
of 	of 	 IN	O
,  	,  	 ,	O
or  	or  	 CC	O
have  	have  	 VBP	O
contraindications  	contraindications  	 VBN	O
to 	to 	 TO	O
,  	,  	 ,	O
three  	three  	 CD	O
oral  	oral  	 JJ	B-NP
glucose-lowering  	glucose-lowering  	 JJ	I-NP
drugs 	drugs 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
liraglutide  	liraglutide  	 CD	B-NP
1.8  	1.8  	 CD	O
mg  	mg  	 NNS	B-NP
was  	was  	 VBD	O
not  	not  	 RB	O
approved  	approved  	 VBN	O
by  	by  	 IN	O
NICE 	NICE 	 NNP	O
.  	.  	 .	O
The  	The  	 DT	O
ERG  	ERG  	 NNP	O
recommends  	recommends  	 VBZ	O
research  	research  	 NN	O
into  	into  	 IN	O
the  	the  	 DT	O
( 	( 	 -LRB-	O
currently  	currently  	 RB	O
unlicensed 	unlicensed 	 CD	O
)  	)  	 -RRB-	O
use  	use  	 NN	O
of  	of  	 IN	O
liraglutide  	liraglutide  	 NN	B-NP
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
long-acting  	long-acting  	 JJ	B-NP
insulin 	insulin 	 NN	I-NP
.  	.  	 .	O
